Roche has launched the Elecsys Troponin T high-sensitive (TNT HS) assay, for use on Cobas and Modular Analytics serum work areas, in the UK and Ireland.
The diagnostic assay has been developed to improve the detection and exclusion of myocardial injury in the early stages, demonstrating high precision in the range of 0.003-10ng/ml Troponin T in serum or plasma, and to help identify risk of future coronary events.
Elecsys TNT HS meets the precision requirements set down in the ACC/ESC guidelines.
In addition, in a recent comparative evaluation, Elecsys TNT HS displayed high sensitivity (95 per cent) and negative predictive value (99 per cent) in the diagnosis of unstable angina at presentation.
This sensitivity and precision is said to make the Elecsys TNT HS assay a valuable tool for the early detection and exclusion of acute myocardial infarction (AMI).
The Elecsys TNT HS assay is further indicated for the risk stratification of patients presenting with acute coronary syndrome (particularly in the risk assessment of chronic renal failure patients), providing an aid in the selection of patients who may require more intensive therapy and intervention.
The robustness of the Elecsys TNT HS assay against interfering factors ensures high result accuracy and consistency in patient follow-up, and the availability of a Stat (nine minutes) version for rapid results delivers fast turnaround time for emergency samples.
Roche offers clinical laboratories the opportunity to consolidate their cardiac marker tests on a single Roche platform.
The Elecsys TNT HS assay is suitable for use on the Modular Analytics, Cobas 8000, Cobas 6000, Cobas 4000 and Elecsys 2010 platforms.
